Literature DB >> 32348499

Response to Cioffi.

Nir Eyal1,2,3, Marc Lipsitch4,5, Peter G Smith6.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32348499     DOI: 10.1093/infdis/jiaa217

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Reply to Hasford and to Spinola et al.

Authors:  Nir Eyal; Marc Lipsitch; Peter G Smith
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

2.  Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.

Authors:  Robert Steel; Lara Buchak; Nir Eyal
Journal:  J Med Ethics       Date:  2020-07-13       Impact factor: 2.903

3.  Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia.

Authors:  Søren Holm
Journal:  J Med Ethics       Date:  2020-07-02       Impact factor: 2.903

4.  Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research.

Authors:  Stanley M Spinola; Camilla Broderick; Gregory D Zimet; Mary A Ott
Journal:  Open Forum Infect Dis       Date:  2020-12-28       Impact factor: 3.835

5.  Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.

Authors:  Nir Eyal
Journal:  Ethics Hum Res       Date:  2020-05-22

6.  Justifying the risks of COVID-19 challenge trials: The analogy with organ donation.

Authors:  Athmeya Jayaram; Jacob Sparks; Daniel Callies
Journal:  Bioethics       Date:  2021-06-27       Impact factor: 2.512

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.